Basic information
- Name:
Pregna-1,4-diene-3,20-dione,21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6a,11b)-
- Superlist Name:
- Methylprednisolone aceponate
- CAS No.:
86401-95-8
- Molecular Structure:

- Formula:
- C27H36O7
- Molecular Weight:
- 472.58
- Synonyms:
- Advantan;ZK 91588;
- Density:
- 1.23 g/cm3
- Boiling Point:
- 595.8 °C at 760 mmHg
- Flash Point:
- 193.1 °C
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Chemistry
Molecular Structure:
.png)
Molecular Formula: C27H36O7
Molecular Weight: 472.5705
IUPAC Name: [(6S,8S,9S,10R,11S,13S,14S,17R)-17-(2-Acetyloxyacetyl)-11-hydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl] propanoate
Synonyms of Methylprednisolone aceponate (CAS NO.86401-95-8): Methylprednisolone aceponate [INN] ; Aceponate de methylprednisolone ; Aceponate de methylprednisolone [French] ; Aceponato de metilprednisolona ; Aceponato de metilprednisolona [Spanish] ; Advantan ; BRN 5663614 ; Methylprednisoloni aceponas ; Methylprednisoloni aceponas [Latin] ; SH-440 ; UNII-ET54W9J4U2 ; ZK91588 ; 11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, 21-acetate 17-propionate ; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6-alpha,11-beta)-
CAS NO: 86401-95-8
Classification Code: Anti-Inflammatory Agents ; Drug / Therapeutic Agent ; Reproductive Effect ; Skin / Eye Irritant
Index of Refraction: 1.559
Molar Refractivity: 123.88 cm3
Molar Volume: 383.1 cm3
Surface Tension: 50.6 dyne/cm
Density: 1.23 g/cm3
Flash Point: 193.1 °C
Enthalpy of Vaporization: 101.88 kJ/mol
Boiling Point: 595.8 °C at 760 mmHg
Vapour Pressure of Methylprednisolone aceponate (CAS NO.86401-95-8): 1.11E-16 mmHg at 25°C
Uses
Methylprednisolone aceponate (CAS NO.86401-95-8) is used for topical cortical steroids hormones.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD50 | oral | > 2gm/kg (2000mg/kg) | GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: INCONTINENCE | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19, Pg. 3015, 1991. |
| rat | LD50 | subcutaneous | > 3gm/kg (3000mg/kg) | ENDOCRINE: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19, Pg. 3015, 1991. |

